Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma

Chamberlain, Marc C.; Baik, Christina S.; Gadi, Vijayakrishna K.; Bhatia, Shailender; Chow, Laura Q.M.

doi:10.1093/neuonc/now197

Cited by 183 publications

(141 citation statements)

References 218 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, lymphatic drainage is individually variable and may lead to false-negative lymph node biopsies due to sampling of wrong nodes (Fincher et al, 2004). Brain metastasis is also more common with head and neck melanomas and confers a worse prognosis (Chamberlain, Baik, Gadi, Bhatia, & Chow, 2017). The location can also make diagnosis and excision difficult.…”

Section: Significancementioning

confidence: 99%

Histopathologic variables differentially affect melanoma survival by age at diagnosis

Mishra

Barnhill

Paddock

et al. 2019

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

We evaluated clinical, phenotypic, behavioral, and histopathologic variables in relationship to melanoma‐specific survival by age at diagnosis among 650 population‐based melanoma patients in Connecticut, with 20 years of follow‐up. Only one variable, skin awareness, was significantly associated with melanoma mortality in both groups. The variables that differed between the age‐groups were anatomic site, Breslow thickness, histologic subtype, mitoses, tumor‐infiltrating lymphocytes (TILs), and solar elastosis. Head and neck melanoma, Breslow thickness, nodular melanoma, and solar elastosis were all significantly more likely to be associated with mortality among the older subjects; among the younger subjects, the presence of mitoses was associated with an increased probability of dying and TILs were associated with a reduced risk of mortality.

show abstract

Section: Significancementioning

confidence: 99%

Histopathologic variables differentially affect melanoma survival by age at diagnosis

Mishra

Barnhill

Paddock

et al. 2019

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

show abstract

“…Brain metastases are devastating complications of lung or breast carcinoma, melanoma and other cancer types, characterized by challenging treatment options. 1,2 Melanoma is the third most common source of brain metastases, 3 but has the highest risk to spread into the central nervous system (CNS). 4 Brain metastatic lesions can be found in approximately three of four patients dying of melanoma.…”

Section: Introductionmentioning

confidence: 99%

Paracellular and transcellular migration of metastatic cells through the cerebral endothelium

Herman

Fazakas

Haskó

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Breast cancer and melanoma are among the most frequent cancer types leading to brain metastases. Despite the unquestionable clinical significance, important aspects of the development of secondary tumours of the central nervous system are largely uncharacterized, including extravasation of metastatic cells through the blood‐brain barrier. By using transmission electron microscopy, here we followed interactions of cancer cells and brain endothelial cells during the adhesion, intercalation/incorporation and transendothelial migration steps. We observed that brain endothelial cells were actively involved in the initial phases of the extravasation by extending filopodia‐like membrane protrusions towards the tumour cells. Melanoma cells tended to intercalate between endothelial cells and to transmigrate by utilizing the paracellular route. On the other hand, breast cancer cells were frequently incorporated into the endothelium and were able to migrate through the transcellular way from the apical to the basolateral side of brain endothelial cells. When co‐culturing melanoma cells with cerebral endothelial cells, we observed N‐cadherin enrichment at melanoma‐melanoma and melanoma‐endothelial cell borders. However, for breast cancer cells N‐cadherin proved to be dispensable for the transendothelial migration both in vitro and in vivo. Our results indicate that breast cancer cells are more effective in the transcellular type of migration than melanoma cells.

show abstract

“…The median OS for patients with NSCLC was 172 days, melanoma was 100 days, and was not applicable in the breast cancer group. The results of this study indicate a low effectiveness of high dose-dense temozolomide regimen for the treatment of brain metastases from NSCLC, BC, and melanoma [24]. (on day 1) IV every 3 weeks, was continued to a maximum of 6 cycles.…”

Section: Type Of Palliative Treatment Indicationsmentioning

confidence: 84%

Management of Brain Metastases from Solid Tumors

Любота¹,

Верещако²,

Anikusko³

et al. 2018

Cancer Management and Therapy

View full text Add to dashboard Cite

Brain metastases (BM) are most common intracranial tumors in adults. Recently, significant progress has been shown in diagnosing, prognosis, and treating patients with BM of various malignant tumors. The treatment decisions must be based on the disease prognosis and include radiation therapy, surgery, systemic antitumor therapy, or a combination thereof. Systemic therapy capable of preventing BM or which affects both intracranial and extracranial disease is of paramount importance in the treatment of BM patients. The purpose of this chapter is to consider important prognostic factors that can determine treatment decisions, review the role of blood-brain barrier (BBB), and systemic anticancer treatment to manage BM from solid tumors.

show abstract

Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma

Cited by 183 publications

References 218 publications

Histopathologic variables differentially affect melanoma survival by age at diagnosis

Histopathologic variables differentially affect melanoma survival by age at diagnosis

Paracellular and transcellular migration of metastatic cells through the cerebral endothelium

Management of Brain Metastases from Solid Tumors

Contact Info

Product

Resources

About